Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2021-03-25 Declaration of Voting R…
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (Annual General Meeting). It details the approval of financial statements, dividend resolutions, election of directors, and other agenda items voted upon during the meeting held on 2021-03-25. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2021-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) by Dongkoo Bio & Pharma. It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit), and details regarding the external auditor. While it contains financial data, it is a specific regulatory disclosure of the audit report submission rather than the full annual report (10-K) or a simple announcement of publication (RPA). Given the focus on the audit opinion and financial results, it fits the 'Audit Report / Information' category. FY 2020
2021-03-17 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Dongkoo Bio & Pharma Co., Ltd. for the fiscal year ending December 31, 2020. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the full company activity report, and it is not an announcement (RPA) because it contains the full financial data. FY 2020
2021-03-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Dongkoo Bio & Pharma regarding a significant change in sales or profit structure (30% or more). This is a standard financial disclosure required by the Korea Exchange (KRX) when a company's financial performance deviates significantly from the previous period. It provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the variance. Since it is an initial announcement of financial results (pre-audit) rather than a full annual report or a simple report publication notice, it falls under the Earnings Release (ER) category. FY 2020
2021-03-10 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Dongkoo Bio & Pharma regarding the decision to pay cash dividends. It specifies the dividend amount per share, the record date, the payment date, and the approval process via the upcoming general meeting of shareholders. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2021-03-10 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for DongKoo Bio & Pharma. It contains the meeting agenda, details on board activities, remuneration, and business reports (management discussion and analysis). This document is provided to shareholders to inform them of the upcoming meeting and to solicit their votes on specific agenda items, which aligns with the definition of Proxy Solicitation & Information Statement.
2021-03-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.